194 related articles for article (PubMed ID: 16062076)
1. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy.
Pacholke HD; Amdur RJ; Morris CG; Li JG; Dempsey JF; Hinerman RW; Mendenhall WM
Am J Clin Oncol; 2005 Aug; 28(4):351-8. PubMed ID: 16062076
[TBL] [Abstract][Full Text] [Related]
2. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
3. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
4. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
7. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
8. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
[TBL] [Abstract][Full Text] [Related]
10. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
[TBL] [Abstract][Full Text] [Related]
11. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
[TBL] [Abstract][Full Text] [Related]
13. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
14. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
15. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
[TBL] [Abstract][Full Text] [Related]
16. Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy.
Lal P; Nautiyal V; Verma M; Yadav R; Maria Das KJ; Kumar S
J Cancer Res Ther; 2018; 14(6):1196-1201. PubMed ID: 30488829
[TBL] [Abstract][Full Text] [Related]
17. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
Meirovitz A; Murdoch-Kinch CA; Schipper M; Pan C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):445-53. PubMed ID: 16839705
[TBL] [Abstract][Full Text] [Related]
18. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
[TBL] [Abstract][Full Text] [Related]
19. Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.
van Dijk LV; Thor M; Steenbakkers RJHM; Apte A; Zhai TT; Borra R; Noordzij W; Estilo C; Lee N; Langendijk JA; Deasy JO; Sijtsema NM
Radiother Oncol; 2018 Sep; 128(3):459-466. PubMed ID: 29958772
[TBL] [Abstract][Full Text] [Related]
20. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
